These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33371122)

  • 1. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients.
    Geng R; Wang G; Qiu L; Liu B; Yang F; Zhang J; Miao Y
    Medicine (Baltimore); 2020 Dec; 99(51):e23719. PubMed ID: 33371122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH
    Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
    Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R
    Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
    Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
    Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.
    Shi M; Ma T; Xi W; Jiang J; Wu J; Zhou C; Yang C; Zhu Z; Zhang J
    Trials; 2020 Mar; 21(1):249. PubMed ID: 32143730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
    Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
    Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
    Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
    Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
    Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.
    Wang ZX; Peng J; Liang X; Cheng Y; Deng Y; Chen K; Zhang M; Zhang J; Wang W; Cao B; Jin Y; Sun M; Lin Y; Luo S; Li Z; Yang L; Ke Y; Yu H; Li J; Wang Q; Zhu J; Wang F; Xu RH
    Med; 2024 Sep; 5(9):1150-1163.e3. PubMed ID: 38870931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
    Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
    Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
    Kerr RS; Love S; Segelov E; Johnstone E; Falcon B; Hewett P; Weaver A; Church D; Scudder C; Pearson S; Julier P; Pezzella F; Tomlinson I; Domingo E; Kerr DJ
    Lancet Oncol; 2016 Nov; 17(11):1543-1557. PubMed ID: 27660192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
    Adams RA; Fisher DJ; Graham J; Seligmann JF; Seymour M; Kaplan R; Yates E; Parmar M; Richman SD; Quirke P; Butler R; Brown E; Collinson F; Falk S; Wasan H; Shiu KK; Middleton G; Samuel L; Wilson RH; Brown LC; Maughan TS;
    J Clin Oncol; 2021 Nov; 39(33):3693-3704. PubMed ID: 34516759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
    Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
    BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
    Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.
    Liu GY; Li WZ; Wang DS; Liang H; Lv X; Ye YF; Zhao C; Ke LR; Lv SH; Lu N; Bei WX; Cai ZC; Chen X; Liang CX; Guo X; Xia WX; Xiang YQ
    JAMA Oncol; 2022 Apr; 8(4):553-561. PubMed ID: 35175316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Gupta N; Verma N; Patel B
    J Gastrointest Cancer; 2024 Dec; 55(4):1485-1497. PubMed ID: 39160369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.